Stelara

Stelara Indications/Uses

ustekinumab

Manufacturer:

Janssen

Distributor:

Zuellig Pharma

Marketer:

Johnson & Johnson
Full Prescribing Info
Indications/Uses
Plaque Psoriasis (via subcutaneous administration only): STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see Pharmacology: Pharmacodynamics under Actions).
Pediatric Plaque Psoriasis (via subcutaneous administration only with single-use vial): STELARA is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see Pharmacology: Pharmacodynamics under Actions).
Psoriatic Arthritis (PsA) (via subcutaneous administration only): STELARA alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see Pharmacology: Pharmacodynamics under Actions).
Crohn's Disease (via intravenous administration for induction dosing, and via subcutaneous administration for maintenance dosing): STELARA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies (see Pharmacology: Pharmacodynamics under Actions).
Ulcerative Colitis (via intravenous administration for induction dosing, and via subcutaneous administration for maintenance dosing): STELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies (see Pharmacology: Pharmacodynamics under Actions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in